BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29899091)

  • 1. Immunization by Replication-Competent Controlled Herpesvirus Vectors.
    Bloom DC; Tran RK; Feller J; Voellmy R
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29899091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Replication-Competent Controlled Herpes Simplex Virus.
    Bloom DC; Feller J; McAnany P; Vilaboa N; Voellmy R
    J Virol; 2015 Oct; 89(20):10668-79. PubMed ID: 26269179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.
    Ryder AB; Buonocore L; Vogel L; Nachbagauer R; Krammer F; Rose JK
    J Virol; 2015 Mar; 89(5):2820-30. PubMed ID: 25540378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuated Herpes Simplex Virus 1 (HSV-1) Expressing a Mutant Form of ICP6 Stimulates a Strong Immune Response That Protects Mice against HSV-1-Induced Corneal Disease.
    Davido DJ; Tu EM; Wang H; Korom M; Gazquez Casals A; Reddy PJ; Mostafa HH; Combs B; Haenchen SD; Morrison LA
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29950407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intramuscular Immunization of Mice with the Live-Attenuated Herpes Simplex Virus 1 Vaccine Strain VC2 Expressing Equine Herpesvirus 1 (EHV-1) Glycoprotein D Generates Anti-EHV-1 Immune Responses in Mice.
    Liu SA; Stanfield BA; Chouljenko VN; Naidu S; Langohr I; Del Piero F; Ferracone J; Roy AA; Kousoulas KG
    J Virol; 2017 Jun; 91(12):. PubMed ID: 28404844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A vectored equine herpesvirus type 1 (EHV-1) vaccine elicits protective immune responses against EHV-1 and H3N8 equine influenza virus.
    Van de Walle GR; May MA; Peters ST; Metzger SM; Rosas CT; Osterrieder N
    Vaccine; 2010 Jan; 28(4):1048-55. PubMed ID: 19897066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic immunization with a virion host shutoff-defective, replication-incompetent herpes simplex virus type 1 strain limits recurrent herpetic ocular infection.
    Keadle TL; Morrison LA; Morris JL; Pepose JS; Stuart PM
    J Virol; 2002 Apr; 76(8):3615-25. PubMed ID: 11907201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase.
    Pavlova SP; Veits J; Keil GM; Mettenleiter TC; Fuchs W
    Vaccine; 2009 Jan; 27(5):773-85. PubMed ID: 19041677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Recombinant HSV-Based Vaccine Vectors.
    Voellmy R; Bloom DC; Vilaboa N; Feller J
    Methods Mol Biol; 2017; 1581():55-78. PubMed ID: 28374243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus.
    Kapczynski DR; Esaki M; Dorsey KM; Jiang H; Jackwood M; Moraes M; Gardin Y
    Vaccine; 2015 Feb; 33(9):1197-205. PubMed ID: 25613723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection of pigs against pandemic swine origin H1N1 influenza A virus infection by hemagglutinin- or neuraminidase-expressing attenuated pseudorabies virus recombinants.
    Klingbeil K; Lange E; Blohm U; Teifke JP; Mettenleiter TC; Fuchs W
    Virus Res; 2015 Mar; 199():20-30. PubMed ID: 25599604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Herpes Simplex Viruses Whose Replication Can Be Deliberately Controlled as Candidate Vaccines.
    Voellmy R; Bloom DC; Vilaboa N
    Vaccines (Basel); 2020 May; 8(2):. PubMed ID: 32443425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of recombinant turkey herpesvirus vaccines targeting the H5 of highly pathogenic avian influenza virus from the 2014-2015 North American outbreak.
    Balzli CL; Bertran K; Lee DH; Killmaster L; Pritchard N; Linz P; Mebatsion T; Swayne DE
    Vaccine; 2018 Jan; 36(1):84-90. PubMed ID: 29180030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.
    Pushko P; Parker M; Ludwig GV; Davis NL; Johnston RE; Smith JF
    Virology; 1997 Dec; 239(2):389-401. PubMed ID: 9434729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses.
    Kapczynski DR; Pantin-Jackwood MJ; Spackman E; Chrzastek K; Suarez DL; Swayne DE
    Vaccine; 2017 Nov; 35(46):6345-6353. PubMed ID: 28456525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice.
    Augustinova H; Hoeller D; Yao F
    J Virol; 2004 Jun; 78(11):5756-65. PubMed ID: 15140973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Replicating Single-Cycle Adenovirus Vectors Generate Amplified Influenza Vaccine Responses.
    Crosby CM; Matchett WE; Anguiano-Zarate SS; Parks CA; Weaver EA; Pease LR; Webby RJ; Barry MA
    J Virol; 2017 Jan; 91(2):. PubMed ID: 27807231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved safety of a replication-competent poxvirus-based HIV vaccine with the introduction of the HSV-TK/GCV suicide gene system.
    Zhang Q; Liu Z; Hou J; Wang S; Liu C; Wei M; Liu Y; Shao Y
    Vaccine; 2016 Jun; 34(30):3447-53. PubMed ID: 27195760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucosal administration of raccoonpox virus expressing highly pathogenic avian H5N1 influenza neuraminidase is highly protective against H5N1 and seasonal influenza virus challenge.
    Kingstad-Bakke B; Kamlangdee A; Osorio JE
    Vaccine; 2015 Sep; 33(39):5155-62. PubMed ID: 26271828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge.
    Davis NL; Brown KW; Johnston RE
    J Virol; 1996 Jun; 70(6):3781-7. PubMed ID: 8648713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.